For many years Harry Glorikian, Managing Director, Scientia Advisors has been helping companies navigate the dynamic, yet increasingly turbulent, life science market. Over the holidays we had the chance to meet with Glorikian to get a peek at what’s in store for several sectors in the healthcare industry in 2012 and beyond. Read more »
The quality of medical treatment is dependent on rapid and accurate diagnosing of the disease, as well as safeguarding the life of the patient. Apart from infectious diseases, most diseases do not have that “tell-all” diagnostic marker that provides an adequate picture of the patient and their particular disease. Seegene, Inc., sees a combination of surrogate markers in a single clinically validated assay as the most effective tool in disease identification, treatment and management, while keeping the patient in focus. Read more »
A partnering forum can be a meeting marathon that is mentally and emotionally exhausting. Industry veteran Stan Yakatan offers some timely tips for getting the most out of your next round of face-to-face presentations with potential partners. Read more »
Mirna Therapeutics expects to select a delivery system for miRNA replacement therapy before the end of this year, positioning the company to arrive first in the clinic with its innovative approach for miRNA mimic compounds. Read more »
The launch of P.L.E.A.S.E.® (Precise Laser Epidermal System) Professional platform by Pantec Biosolutions is the leading edge of the company’s strategy for its novel, pain-free intraepidermal delivery system that will have applications for a wide range of drugs. Read more »
Selecting the appropriate chemotherapy for individual women with ovarian cancer is still a trial and error endeavor that involves more than a dozen different potential therapies. Finding the right drug takes time, delays effective treatment and is expensive, both for patients and for insurers. The Clearity Foundation is working to change that. Read more »
Interview with expert dealmaker Fran Heller, EVP at Exelixis, who discusses the art of the deal in life science. Read more »
To evaluate a medical product’s viability in the marketplace, a company must fully understand the clinical care pathway, the “disruptive” impact the product could have, and the economics that will be involved. Read more »
Newsletter